Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
$2.58
+4.0%		$2.56
$2.20
▼
$6.52
$20.31M0.5539,273 shs29,348 shs
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$1.43
+4.4%		$1.76
$1.13
▼
$3.78
$21.41M1.08365,975 shs997,927 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.50
$0.57
$0.26
▼
$17.20
$6.61M0.53399,279 shs42,423 shs
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$28.33
-0.8%		$32.62
$14.03
▼
$79.75
$18.98M244,151 shs93,278 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-5.77%-2.78%-6.84%-20.71%-44.57%
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-4.86%+3.01%-33.82%-36.87%-35.07%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
+9.55%+5.65%-8.44%+51.73%-94.52%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
0.00%0.00%-20.32%-15.45%+63.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
$2.58
+4.0%		$2.56
$2.20
▼
$6.52
$20.31M0.5539,273 shs29,348 shs
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$1.43
+4.4%		$1.76
$1.13
▼
$3.78
$21.41M1.08365,975 shs997,927 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.50
$0.57
$0.26
▼
$17.20
$6.61M0.53399,279 shs42,423 shs
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$28.33
-0.8%		$32.62
$14.03
▼
$79.75
$18.98M244,151 shs93,278 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-5.77%-2.78%-6.84%-20.71%-44.57%
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-4.86%+3.01%-33.82%-36.87%-35.07%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
+9.55%+5.65%-8.44%+51.73%-94.52%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
0.00%0.00%-20.32%-15.45%+63.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
2.80
Moderate Buy$11.00326.52% Upside
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
2.33
Hold$10.00599.30% Upside
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
2.50
Moderate Buy$66.6713,114.40% Upside
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest RVPH, CLRB, DARE, and VYNE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/12/2026
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
Brookline Capital Markets logo
Brookline Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
5/15/2026
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
LADENBURG THALM/SH SH logo
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/A$1.89 per shareN/A
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$1.16M18.63N/AN/A$0.20 per share7.15
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/A$1.48 per shareN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$570K33.29N/AN/A$41.71 per share0.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$21.79M-$6.66N/AN/AN/AN/A-349.24%-153.18%10/29/2026 (Estimated)
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$13.40M-$0.95N/AN/AN/AN/AN/A-46.22%N/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$19.86M-$4.06N/AN/AN/AN/A-391.58%-119.08%N/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$26.48M-$0.38N/AN/AN/A-4,726.21%-70.42%-63.46%N/A

Latest RVPH, CLRB, DARE, and VYNE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$0.5875-$0.57+$0.0175-$0.57$12.00 millionN/A
8/13/2026Q2 2026
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$0.2967-$0.20+$0.0967-$0.20$0.00 million$0.19 million
8/13/2026Q2 2026
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$0.18-$3.51-$3.33-$3.51$0.20 million$0.10 million
5/15/2026Q1 2026
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$9.00-$4.00+$5.00-$0.08$0.20 million$0.09 million
5/14/2026Q1 2026
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$1.8850-$1.33+$0.5550-$1.33$8.00 millionN/A
5/14/2026Q1 2026
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$0.33-$0.20+$0.13-$0.21$0.03 million$0.15 million
5/14/2026Q1 2026
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.3550-$0.46-$0.1050-$0.46N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/AN/A
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/AN/AN/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
N/AN/AN/AN/AN/A

Latest RVPH, CLRB, DARE, and VYNE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/10/2026
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
special$19.007/22/20267/23/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/A
1.90
1.90
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/A
1.03
1.03
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/A
2.08
2.08
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
N/A
20.86
20.86

Institutional Ownership

CompanyInstitutional Ownership
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
16.41%
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
6.70%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
63.18%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
83.78%

Insider Ownership

CompanyInsider Ownership
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
2.58%
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
4.10%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
8.90%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
3.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
107.99 million7.79 millionNo Data
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
3015.08 million14.46 millionNot Optionable
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
513.11 million11.67 millionOptionable
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
30670,000648,000Not Optionable

Recent News About These Companies

VYNE Therapeutics (VYNE) Projected to Post Earnings on Thursday
August 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943601
Guardian Pharmacy Services (NYSE:GRDN) versus VYNE Therapeutics (NASDAQ:VYNE) Critical Contrast
August 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30938621
Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101
July 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/yarrow-bioscience-completes-vyne-therapeutics-131723756.html
VYNE Therapeutics (NASDAQ:VYNE) Sees Large Volume Increase - Here's Why
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vyne-therapeutics-nasdaqvyne-sees-large-volume-increase-heres-why-2026-07-27/
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves ...
July 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/yarrow-bioscience-announces-closing-merger-110000899.html
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3332602/0/en/vyne-therapeutics-provides-update-regarding-cash-dividend-reverse-stock-split-and-anticipated-timing-of-closing-of-the-proposed-merger-with-yarrow-bioscience.html
VYNE Therapeutics Inc.: VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with ...
July 22, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69082373-vyne-therapeutics-inc-vyne-therapeutics-announces-1-for-50-reverse-stock-split-and-provides-update-regarding-special-dividend-in-connection-with-the-399.htm
VYNE Therapeutics (NASDAQ:VYNE) Draws Technical Attention After Reverse Split Update
July 22, 2026  |  kalkinemedia.comK
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330398/0/en/vyne-therapeutics-announces-1-for-50-reverse-stock-split-and-provides-update-regarding-special-dividend-in-connection-with-the-proposed-merger-with-yarrow-bioscience.html
Vyne Therapeutics (NASDAQ:VYNE): What’s Behind the Special Dividend?
July 10, 2026  |  kalkinemedia.comK
VYNE Therapeutics Announces Special Cash Dividend in Connection with Pending Merger with Yarrow Bioscience
July 10, 2026  |  quiverquant.comQ
VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
July 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/10/3325444/0/en/vyne-therapeutics-declares-special-cash-dividend-in-connection-with-the-proposed-merger-with-yarrow-bioscience.html
VYNE Therapeutics Insider Trading Activity | NASDAQ:VYNE | Benzinga
July 1, 2026  |  benzinga.comhttps://www.benzinga.com/quote/VYNE/insider-trades
VYNE Therapeutics (VYNE) price target decreased by 38.46% to 2.04
May 15, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/vyne-therapeutics-vyne-price-target-decreased-by-38-46-to-2-04/ar-AA23dejj
Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
December 18, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/shareholder-alert-the-ademi-firm-investigates-whether-vyne-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302646437.html
3 penny stocks to watch now, 12/18/25
December 18, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/3-penny-stocks-to-watch-now-12-18-25/ar-AA1SC3AZ
VYNE to merge with Yarrow in $200 million deal
December 18, 2025  |  thepharmaletter.comT
Roundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow Bioscience
December 17, 2025  |  pharmexec.comP
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)
December 17, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-vyne-therapeutics-inc-nasdaq-vyne-302645150.html
VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders
December 17, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251217467188/en/VYNE-Stock-Alert-Halper-Sadeh-LLC-is-Investigating-Whether-the-Merger-of-VYNE-Therapeutics-Inc.-is-Fair-to-Shareholders/
VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript
December 17, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4854136-vyne-therapeutics-inc-vyne-yarrow-bioscience-inc-m-and-a-call-prepared-remarks-transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
Trading screen displaying a candlestick price chart, options calls and puts pricing table, and green call, red put buttons.
The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
By Bridget Bennett | July 20, 2026
SK hynix logo above a robotic arm placing memory chips on a wafer in a server data center.
Why SK hynix Could Be the Best AI Chip Stock to Buy Now
By Thomas Hughes | July 29, 2026
Ryman Hospitality Properties, Inc. logo overlaid on an aerial dusk view of downtown Nashville with the Ryman Auditorium and Gaylord Opryland.
Ryman Checks Into a $1.38B Hospitality Upgrade
By Jeffrey Neal Johnson | August 13, 2026
Cellectar Biosciences stock logo

Cellectar Biosciences NASDAQ:CLRB

$2.58 +0.10 (+3.99%)
As of 09:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Dare Bioscience stock logo

Dare Bioscience NASDAQ:DARE

$1.43 +0.06 (+4.38%)
As of 09:45 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Reviva Pharmaceuticals stock logo

Reviva Pharmaceuticals NASDAQ:RVPH

$0.50 0.00 (0.00%)
As of 08/13/2026 03:45 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

VYNE Therapeutics stock logo

VYNE Therapeutics NASDAQ:VYNE

$28.32 -0.24 (-0.82%)
Closing price 07/27/2026
Extended Trading
$28.32 0.00 (0.00%)
As of 07/27/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas